Castle Biosciences Inc. (CSTL) is a renowned commercial-stage dermatological cancer company headquartered in Friendswood, Texas, USA. The company began its operations in 2007 and since then has dedicated its services to developing and commercializing diagnostic and prognostic tests designed to provide physicians and their patients with more accurate and actionable information to guide treatment decisions.
The core philosophy of Castle Biosciences centers around improving health outcomes through more accurate diagnoses. They harness innovations in genomics to create diagnostic tests that, they believe, take the guesswork out of identifying potentially deadly conditions, like uveal (eye) and cutaneous (skin) melanoma, at their earliest and most treatable stages.
Their portfolio of tests prominently features DecisionDx®-Melanoma, a gene expression profile (GEP) test for use in patients diagnosed with melanoma, and DecisionDx®-UM, a GEP test for use in patients diagnosed with uveal melanoma. Both of these tests are designed to predict individual risk of metastasis. Castle Biosciences holds an extensive patent portfolio for its proprietary tests and has been commended for its meticulous research and development process.
Besides cutaneous melanoma and uveal melanoma, the company also offers a prognosis test for cutaneous squamous cell carcinoma, and another that can help to identify the risk of the recurrence of skin cancer. This multifaceted approach towards dermatological cancers showcases the company's commitment to pioneering new ways to combat and manage these diseases.
Despite their focus on dermatological cancers, Castle Biosciences is always on the lookout for opportunities to expand its suite of diagnostic solutions. They are committed to improving the lives of patients across a wide spectrum of cancers and diseases, and it is this patient-centric mindset that informs their continual research and development efforts.
As a publicly-traded company listed on the NASDAQ, Castle Biosciences has become a trusted name in the healthcare industry. The company's steady growth and resilient business model emphasizes their vision to bring the power of genomics to bear on challenging diagnostic problems. It is a leading force in innovative healthcare solutions, enabling patients and physicians to make informed treatment decisions and redefine the trajectory of cancer care outcomes around the world.